The Dow Jones Industrial Average (^DJI) was down 821.91 (-1.66%) points today, closing at 48,804.06, while Dow Futures (YM=F) fell 857.00 (-1.73%) to 48,817.00. The main narrative driving the market was a sudden 15% blanket tariff announcement, which reignited trade war fears and global economic uncertainty. This policy shift, combined with hawkish Federal Reserve commentary suggesting a "coin flip" for future rate cuts, triggered a massive rotation out of cyclical and growth sectors into defensive assets.F ...

Transaction expected to be accretive to earnings per share from 2028 onwards.Deal provides full control of anito-cel, an investigational CAR-T therapy for multiple myeloma.Gilead Moves Into CAR-T Oncology With Arcellx AcquisitionGilead Sciences just made a big move, announcing a $7.8 billion deal to buy Arcellx. It’s their biggest acquisition since 2020, signaling they’re serious about moving beyond just HIV and liver disease treatments.Arcellx shares shot up right after the news. Gilead’s offering $115 per ...

The Dow Jones Industrial Average (^DJI) was down 798.40 (-1.61%) points today, currently sitting at 48,827.57. Similarly, Dow Futures (YM=F) was down 742.00 (-1.49%) points. The primary narrative driving this sharp decline was a significant "risk-off" rotation triggered by renewed concerns over stubborn inflation data and a potential hawkish shift in monetary policy. This sentiment disproportionately affected the financial and technology sectors, as investors moved capital away from growth-oriented and cred ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

The Dow Jones Industrial Average (^DJI) was down 715.91 (-1.44%) points today, reaching 48,910.06, while Dow Futures (YM=F) was down 740.00 (-1.49%) points. The primary narrative driving the market lower is a sharp retreat in the financial and technology sectors, sparked by a hawkish shift in monetary policy expectations and rising concerns over consumer credit health. Investors are rotating out of cyclical names in favor of defensive havens as economic uncertainty regarding interest rate trajectories for t ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBayer files lawsuit against Johnson & Johnson, Janssen BiotechFebruary 23, 20263:43 PM UTCUpdated agoBy ReutersThe 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical... Purchase Licensing Rights, opens new tab Read moreCompaniesBayer AGJanssen Biotech IncJohnson ...

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

Core Insights - The European Commission has approved subcutaneous (SC) amivantamab, allowing for administration in minutes rather than hours, with efficacy and safety consistent with intravenous (IV) amivantamab [1][2][3] - SC amivantamab is now authorized for all previously approved IV indications, including every-four-week (Q4W) and every-three-week (Q3W) dosing regimens for advanced non-small cell lung cancer (NSCLC) [1][2][3][4] - The new dosing options aim to reduce administration-related reactions and improve patient convenience [1][2][3][4] Company Developments - Johnson & Johnson announced the approval of SC amivantamab, which is expected to enhance the treatment experience for patients with EGFR-mutated NSCLC [1][2][3] - The approval is part of Johnson & Johnson's commitment to improving patient care and treatment flexibility [1][2][3] Clinical Study Results - The approval is supported by Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which demonstrated that SC amivantamab has a response rate and safety profile similar to IV amivantamab, but with significantly fewer administration-related reactions [1][2][3][4] - Administration time for SC amivantamab is approximately five minutes, compared to five hours for the first IV infusion [1][2][3][4] Treatment Context - Amivantamab is a bispecific antibody targeting EGFR and MET mutations, which are prevalent in NSCLC [3][4] - The approval of SC amivantamab aligns with the growing need for more efficient treatment options in the context of lung cancer, which is the leading cause of cancer-related deaths in Europe [6][7]

Company Overview - Johnson & Johnson (J&J) is a leading company in the multitrillion-dollar global healthcare industry, with total healthcare spending in the U.S. surpassing $5.3 trillion in 2024 and growing at mid- to high single-digit rates [3] - The company develops and sells a wide range of pharmaceutical drugs and medical devices, with over 75% of its sales coming from products that hold top-two market share positions in their respective applications [4] Financial Strength - J&J has a strong financial position, allowing it to invest in new product development, acquire emerging competitors, and consistently raise its dividend [5] - The stock currently yields 2.1%, with management having raised the dividend for 63 consecutive years, making it a reliable income source for investors [6] - J&J is one of only two companies with the highest available credit rating (AAA), ensuring access to debt when needed [6] Market Position and Growth Potential - With a market capitalization approaching $590 billion, J&J is one of the world's largest companies, indicating stability rather than rapid wealth generation [7] - Management believes that the business could accelerate to double-digit growth by the end of this decade, suggesting potential upside for investors [7]

Core Viewpoint - Johnson & Johnson is considered a stable investment option, providing steady income and strong total returns, making it a reliable choice for investors seeking long-term growth [1]. Group 1: Dividend Performance - Johnson & Johnson has raised its dividend for 63 consecutive years, qualifying it as a "Dividend King" [3]. - The company has achieved a total dividend increase of 73% over the past decade, with a recent quarterly payout increase of 4.8% to $1.30 per share, resulting in a yield of 2.1% [4]. - The payout ratio stands at 46.3%, indicating sufficient capacity for continued dividend increases, with $12.4 billion paid in dividends against $20 billion in free cash flow in 2025 [5]. Group 2: Financial Performance - Over the past year, Johnson & Johnson's total return exceeded 60%, significantly outpacing the S&P 500's return [7]. - The company reported a revenue increase of 6% to $94.2 billion and a remarkable 90.5% growth in earnings per share (EPS) to $11.03, with adjusted EPS rising by 8.1% to $10.79 [8]. Group 3: Future Growth and Innovation - Johnson & Johnson is investing $1 billion in a new cell manufacturing facility in Pennsylvania, aiming to enhance domestic production of advanced medicines [9]. - The company plans to allocate $55 billion towards U.S. manufacturing, research and development, and technology through early 2029 [10]. - In 2025, Johnson & Johnson invested $14.6 billion in R&D, leading to 28 programs generating over $1 billion in sales and 51 approved therapies in its innovative medicine division [11].